Clinical Trials Logo

CDI clinical trials

View clinical trials related to CDI.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05508607 Completed - CDI Clinical Trials

Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention

PASTCDI
Start date: May 1, 2021
Phase:
Study type: Observational

To decrease CDI incidence by implementing an electronic health record-integrated CDI-risk classification tool for Clostridioides difficile infection (CDI) to focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.

NCT ID: NCT03788434 Completed - Clinical trials for Clostridium Difficile Infection

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

CONSORTIUM
Start date: February 8, 2019
Phase: Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

NCT ID: NCT03621657 Completed - Clinical trials for Clostridium Difficile Infection

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

GRAFT
Start date: March 21, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the gut microbiota and clinical outcomes of oral FMT during antibiotic treatment, immediately following antibiotic treatment, and placebo. The second objective is to assess the safety and feasibility of daily oral Fecal Microbiome Transplant (FMT) as a treatment option.

NCT ID: NCT03497806 Completed - Clinical trials for Clostridium Difficile Infection

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

PRISM-EXT
Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible for direct study entry into CP101-CDI-E02. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in he study and administered CP101. Approximately 200 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.

NCT ID: NCT03462459 Completed - Clinical trials for Clostridium Difficile Infection

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Start date: May 21, 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.